Acta Neuropathologica

, Volume 127, Issue 6, pp 811–824

TDP-43 is a key player in the clinical features associated with Alzheimer’s disease

  • Keith A. Josephs
  • Jennifer L. Whitwell
  • Stephen D. Weigand
  • Melissa E. Murray
  • Nirubol Tosakulwong
  • Amanda M. Liesinger
  • Leonard Petrucelli
  • Matthew L. Senjem
  • David S. Knopman
  • Bradley F. Boeve
  • Robert J. Ivnik
  • Glenn E. Smith
  • Clifford R. JackJr.
  • Joseph E. Parisi
  • Ronald C. Petersen
  • Dennis W. Dickson
Original Paper

DOI: 10.1007/s00401-014-1269-z

Cite this article as:
Josephs, K.A., Whitwell, J.L., Weigand, S.D. et al. Acta Neuropathol (2014) 127: 811. doi:10.1007/s00401-014-1269-z

Abstract

The aim of this study was to determine whether the TAR DNA-binding protein of 43 kDa (TDP-43) has any independent effect on the clinical and neuroimaging features typically ascribed to Alzheimer’s disease (AD) pathology, and whether TDP-43 pathology could help shed light on the phenomenon of resilient cognition in AD. Three-hundred and forty-two subjects pathologically diagnosed with AD were screened for the presence, burden and distribution of TDP-43. All had been classified as cognitively impaired or normal, prior to death. Atlas-based parcellation and voxel-based morphometry were used to assess regional atrophy on MRI. Regression models controlling for age at death, apolipoprotein ε4 and other AD-related pathologies were utilized to explore associations between TDP-43 and cognition or brain atrophy, stratified by Braak stage. In addition, we determined whether the effects of TDP-43 were mediated by hippocampal sclerosis. One-hundred and ninety-five (57 %) cases were TDP-positive. After accounting for age, apolipoprotein ε4 and other pathologies, TDP-43 had a strong effect on cognition, memory loss and medial temporal atrophy in AD. These effects were not mediated by hippocampal sclerosis. TDP-positive subjects were 10× more likely to be cognitively impaired at death compared to TDP-negative subjects. Greater cognitive impairment and medial temporal atrophy were associated with greater TDP-43 burden and more extensive TDP-43 distribution. TDP-43 is an important factor in the manifestation of the clinico-imaging features of AD. TDP-43 also appears to be able to overpower what has been termed resilient brain aging. TDP-43 therefore should be considered a potential therapeutic target for the treatment of AD.

Keywords

TDP-43 Alzheimer disease Resilience APOE ε4 Braak stage MRI 

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Keith A. Josephs
    • 1
  • Jennifer L. Whitwell
    • 2
  • Stephen D. Weigand
    • 3
  • Melissa E. Murray
    • 7
  • Nirubol Tosakulwong
    • 3
  • Amanda M. Liesinger
    • 7
  • Leonard Petrucelli
    • 8
  • Matthew L. Senjem
    • 4
  • David S. Knopman
    • 1
  • Bradley F. Boeve
    • 1
  • Robert J. Ivnik
    • 6
  • Glenn E. Smith
    • 6
  • Clifford R. JackJr.
    • 2
  • Joseph E. Parisi
    • 5
  • Ronald C. Petersen
    • 1
  • Dennis W. Dickson
    • 7
  1. 1.Department of Neurology (Behavioral Neurology)Mayo ClinicRochesterUSA
  2. 2.Department of Radiology (Radiology Research)Mayo ClinicRochesterUSA
  3. 3.Department of Health Science Research (Biostatistics)Mayo ClinicRochesterUSA
  4. 4.Department of Information TechnologyMayo ClinicRochesterUSA
  5. 5.Department of Laboratory Medicine and NeuropathologyMayo ClinicRochesterUSA
  6. 6.Department of Neuropsychiatry (Neuropsychology)Mayo ClinicRochesterUSA
  7. 7.Department of Neuroscience (Neuropathology)Mayo ClinicJacksonvilleUSA
  8. 8.Molecular NeuroscienceMayo ClinicJacksonvilleUSA

Personalised recommendations